Discovery of Cytochrome P450 1B1 Inhibitors as New Promising Anti-Cancer Agents

Medicinal Research Reviews

Volumn 23, Issue 6, 2003, Pages 657-668

  Chun, Young Jin ^a   Kim, Sanghee ^b  

^a Chung Ang University   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Anti cancer; CYP1 inhibitors; Cytochrome P450 1B1; Natural products; Stilbene

Indexed keywords

8 ACYLUMBELLIFERONE; ACACETIN; ALPHA NAPHTHOFLAVONE; ANTINEOPLASTIC AGENT; BERGAMOTTIN; CORIANDERIN; CYTOCHROME P450 1B1; CYTOCHROME P450 1B1 INHIBITORS; DIOSMETIN; ENZYME INHIBITOR; ERIODICTYOL; GALANGIN; HESPERETIN; HOMOERIODICTYOL; ISOPIMPINELLIN; METHOXSALEN; NARINGENIN; PENTOSALEN; POLYCYCLIC AROMATIC HYDROCARBON; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; DRUG ACTIVITY; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME INHIBITION; ESTROGEN METABOLISM; METABOLISM; PROTEIN EXPRESSION; PROTEIN FAMILY; REVIEW; TREATMENT PLANNING;

ANTINEOPLASTIC AGENTS; ARYL HYDROCARBON HYDROXYLASES; FEMALE; FORECASTING; HUMANS; MALE; NEOPLASMS; SENSITIVITY AND SPECIFICITY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0142231975     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.10050     Document Type: Review

References (69)

1. Wrighton SA, Stevens JC. The human hepatic cytochrome P450 involved in drug metabolism. Crit Rev Toxicol 1992;22:1-21.
2. Kadlubar FF, Hammons GJ. The role of cytochrome P-450 in the metabolism of chemical carcinogens. In: Mammalian cytochromes P-450. Boca Raton: CRC Press; 1987. pp 81-130.
3. Guengerich FP, Shimada T. Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem Res Toxicol 1991;4:381-407.
4. Lewis DFV, Moereels H, Lake BG, Ioannides C, Parke DV. Molecular modeling of enzymes and receptors involved in carcinogenesis: QSARs and compact-3D. Drug Metab Rev 1994;26:261-285.
5. Shimada T, Yun CH, Yamazaki H, Gautier JC, Beaune PH, Guengerich FP. Characterization of human lung microsomal cytochrome P-450 1A1 and its role in the oxidation of chemical carcinogens. Mol Pharmacol 1992;41:856-864.
6. Raney KD, Shimada T, Kim DH, Groopman JD, Harris TM, Guengerich FP. Oxidation of aflatoxins and sterigmatocystin by human liver microsomes: Significance of aflatoxin Q1 as a detoxication product of aflatoxin B1. Chem Res Toxicol 1992;5:202-210.
7. Butler MA, Iwasaki M, Guengerich FP, Kadlubar FF. Human cytochrome P-450PA (P-4501A2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci USA 1989;86:7696-7700.
8. Sutter TR, Guzman K, Dold KM, Greenlee WF. Targets for dioxin: Genes for plasminogen activator inhibitor-2 and interleukin-1. Science 1991;254:415-418.
9. Sutter TR, Tang YM, Hayes CL, Wo YY, Jabs EW, Li X, Yin H, Cody CW, Greenlee WF. Complete cDNA sequence of a human dioxin-inducible mRNA identifies a new gene subfamily of cytochrome P450 that maps to chromosome 2. J Biol Chem 1994;269:13092-13099.
10. Quattrochi LC, Okino ST, Pendurthi UR, Tukey RH. Cloning and isolation of human cytochrome P-450 cDNAs homologous to dioxin-inducible rabbit mRNAs encoding P-450 4 and P-450 6. DNA 1985;4:395-400.
11. Jaiswal AK, Gonzalez FJ, Nebert DW. Human dioxin-inducible cytochrome P1-450: Complementary DNA and amino acid sequence. Science 1985;228:80-83.
12. Hayes CL, Spink DC, Spink BC, Cao JQ, Walker NJ, Sutter TR. 17β-Estradiol hydroxylation catalyzed by human cytochrome P450 1B1. Proc Natl Acad Sci USA 1996;93:9776-9781.
13. Murray GI, Taylor MC, McFadyen MC, McKay JA, Greenlee WF, Burke MD, Melvin WT. Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res 1997;57:3026-3031.
14. Savas Ü, Bhattacharyya KK, Christou M, Alexander DL, Jefcoate CR. Mouse cytochrome P-450EF, representative of a new 1B subfamily of cytochrome P-450s. Cloning, sequence determination, and tissue expression. J Biol Chem 1994;269:14905-14911.
15. Shen Z, Liu J, Wells RL, Elkind MM. cDNA cloning, sequence analysis, and induction by aryl hydrocarbons of a murine cytochrome P450 gene, CYP1B1. DNA Cell Biol 1994;13:763-769.
16. Walker NJ, Gastel JA, Costa LT, Clark GC, Lucier GW, Sutter TR. Rat CYP1B1: An adrenal cytochrome P450 that exhibits sex-dependent expression in livers and kidneys of TCDD-treated animals. Carcinogenesis 1995;16:1319-1327.
17. Bhattacharyya KK, Brake PB, Eltom SE, Otto SA, Jefcoate CR. Identification of a rat adrenal cytochrome P450 active in polycyclic hydrocarbon metabolism as rat CYP1B1. J Biol Chem 1995;270:11595-11602.
18. Tang YM, Wo YY, Stewart J, Hawkins AL, Griffin CA, Sutter TR, Greenlee WF. Isolation and characterization of the human CYP1B1 gene. J Biol Chem 1996;271:28324-28330.
19. Otto S, Bhattacharyya KK, Jefcoate CR. Polycyclic aromatic hydrocarbon metabolism in rat adrenal, ovary, and testis microsomes is catalyzed by the same novel cytochrome P450 (P450RAP). Endocrinology 1992;131:3067-3076.
20. Pottenger LH, Christou M, Jefcoate CR. Purification and immunological characterization of a novel cytochrome P450 from C3H/10T1/2 cells. Arch Biochem Biophys 1991;286:488-497.
21. Shimada T, Wunsch RM, Hanna IH, Sutter TR, Guengerich FP, Gillam EMJ. Recombinant human cytochrome P450 1B1 expression in Escherichia coli. Arch Biochem Biophys 1998;357:111-120.
22. Crespi CL, Penman BW, Steimel DT, Smith T, Yang CS, Sutter TR. Development of a human lymphoblastoid cell line constitutively expressing human CYP1B1 cDNA: Substrate specificity with model substrates and promutagens. Mutagenesis 1997;12:83-89.
23. Shimada T, Hayes CL, Yamazaki H, Amin S, Hecht SS, Guengerich FP, Sutter TR. Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. Cancer Res 1996;56:2979-2984.
24. Guengerich FP, Chun YJ, Kim D, Gillam EMJ, Shimada T. Cytochrome P450 1B1: A target for inhibition in anticarcinogenesis strategies. Mutat Res 2003;523-524:173-182.
25. Aoyama T, Korzekwa K, Nagata K, Gillette J, Gelboin HV, Gonzalez FJ. Estradiol metabolism by complementary deoxyribonucleic acid-expressed human cytochrome P450s. Endocrinology 1990;126:3101-3106.
26. Kerlan V, Dreano Y, Bercovici JP, Beaune PH, Floch HH, Berthou F. Nature of cytochromes P450 involved in the 2-/4-hydroxylations of estradiol in human liver microsomes. Biochem Pharmacol 1992;44:1745-1756.
27. Yager JD, Liehr JG. Molecular mechanisms of estrogen carcinogenesis. Ann Rev Pharmacol Toxicol 1996;36:203-232.
28. MacLusky NJ, Naftolin F, Krey LC, Franks S. The catechol estrogens. J Steroid Biochem 1981;15:111-124.
29. Franks S, MacLusky NJ, Naftolin F. Comparative pharmacology of oestrogens and catechol oestrogens: Actions on the immature rat uterus in vivo and in vitro. J Endocrinol 1982;94:91-98.
30. Franks S, MacLusky NJ, Naish SJ, Naftolin F. Actions of catechol oestrogens on concentrations of serum luteinizing hormone in the adult castrated rat: Various effects of 4-hydroxyoestradiol and 2-hydroxyoestradiol. J Endocrinol 1981;89:289-295.
31. van Aswegen CH, Purdy RH, Wittliff JL. Binding of 2-hydroxyestradiol and 4-hydroxyestradiol to estrogen receptors from human breast cancers. J Steroid Biochem 1989;32:485-492.
32. Barnea ER, MacLusky NJ, Naftolin F. Kinetics of catechol estrogen-estrogen receptor dissociation: A possible factor underlying differences in catechol estrogen biological activity. Steroids 1983;41:643-656.
33. MacLusky NJ, Barnea ER, Clark CR, Naftolin F. Catechol estrogens and estrogen receptors. In: Catechol estrogens. New York: Raven Press; 1983. pp 151-165.
34. Cavalieri EL, Stack DE, Devanesan PD, Todorovic R, Dwivedy I, Higginbotham S, Johansson SL, Patil KD, Gross ML, Gooden JK, Ramanathan R, Cerny RL, Rogan EG. Molecular origin of cancer: Catechol estrogen-3,4-quinones as endogenous tumor initiators. Proc Natl Acad Sci USA 1997;94:10937-10942.
35. Stack DE, Byun J, Gross ML, Rogan EG, Cavalieri EL. Molecular characteristics of catechol estrogen quinines in reaction with deoxyribonucleosides. Chem Res Toxicol 1996;9:851-859.
36. Liehr JG, Ricci MJ. 4-Hydroxylation of estrogens as marker of human mammary tumors. Proc Natl Acad Sci USA 1996;93:3294-3296.
37. Liehr JG. Dual role of oestrogens as hormones and pro-carcinogens: Tumor initiation by metabolic activation of oestrogens. Eur J Cancer Prev 1997;6:3-10.
38. Weisz J, Bui QD, Roy D, Liehr JG. Elevated 4-hydroxylation of estradiol by hamster kidney microsomes: A potential pathway of metabolic activation of estrogens. Endocrinology 1992;131:655-661.
39. McKay JA, Melvin WT, Ah-See AK, Ewen SWB, Greenlee WF, Marcus CB, Burke MD, Murray GI. Expression of cytochrome P450 CYP1B1 in breast cancer. FEBS Lett 1995;374:270-272.
40. Buters JTM, Sakai S, Richter T, Pineau T, Alexander DL, Savas U, Doehmer J, Ward JM, Jefcoate CR, Gonzalez FJ. Cytochrome P450 CYP1B1 determines susceptibility to 7,12-dimethylbenz[a]anthracene-induced lymphomas. Proc Natl Acad Sci USA 1999;96:1977-1982.
41. Parikh A, Gillam EMJ, Guengerich FP. Drug metabolism by Escherichia coli expressing human cytochromes P450. Nat Biotechnol 1997;15:784-788.
42. Shimada T, Yamazaki H, Foroozesh M, Hopkins NE, Alworth WL, Guengerich FP. Selectivity of polycyclic inhibitors for human cytochrome P450s 1A1, 1A2, and 1B1. Chem Res Toxicol 1998;11:1048-1056.
43. Foroozesh M, Primrose G, Guo Z, Bell LC, Alworth WL, Guengerich FP. Aryl acetylenes as mechanism-based inhibitors of cytochrome P450-dependent monooxygenase enzymes. Chem Res Toxicol 1997;10:91-102.
44. Pang S, Cao JQ, Katz BH, Hayes CL, Sutter TR, Spink DC. Inductive and inhibitory effects of non-ortho-substituted polychlorinated biphenyls on estrogen metabolism and human cytochromes P450 1A1 and 1B1. Biochem Pharmacol 1999;58:29-38.
45. Mays D, Hilliard J, Wong D, Chambers M, Park S, Gelboin H, Gerber N. Bioactivation of 8-methoxypsoralen and irreversible inactivation of cytochrome P-450 in mouse liver microsomes: Modification by monoclonal antibodies, inhibition of drug metabolism, and distribution of covalent adducts. J Pharmacol Exp Ther 1990;254:720-731.
46. Stupans I, Ryan AJ. In vitro inhibition of 3-methylcholanthrene-induced rat hepatic aryl hydrocarbon hydroxylase by 8-acyl-7-hydroxycoumarins. Structure-activity relationships and metabolite profiles. Biochem Pharmacol 1984;33:131-139.
47. Kleiner HE, Vulimiri SV, Reed MJ, Uberecken A, DiGiovanni J. Role of cytochrome P450 1a1 and 1b1 in the metabolic activation of 7,12-dimethylbenz[a]anthracene and the effects of naturally occurring furanocoumarins on skin tumor initiation. Chem Res Toxicol 2002;15:226-235.
48. Cai Y, Baer-Dubowska W, Ashwood-Smith MJ, Ceska O, Tachibana S, DiGiovanni J. Mechanism-based inactivation of hepatic ethoxyresorufin O-dealkylation activity by naturally occurring coumarins. Chem Res Toxicol 1996;9:729-736.
49. Harborne JB, Baxter H, Moss GP. Phytochemical dictionary. Philadelphia: Taylor & Francis; 1999. pp 1-976.
50. So FV, Guthrie N, Chambers AF, Moussa M, Carroll KK. Inhibition of human breast cancer cell proliferation and delay of mammary tumorigenesis by flavonoids and citrus juices. Nutr Cancer 1996;262:167-181.
51. Wattenberg LW. Inhibition of carcinogenesis by minor dietary constituents. Cancer Res 1992;52:2085s-2091s.
52. Zhai S, Dai R, Wei X, Friedman FK, Vestal RE. Inhibition of methoxyresorufin demethylase activity by flavonoids in human liver microsomes. Life Sci 1998;63:PL119-PL123.
53. Zhai S, Dai R, Friedman FK, Vestal RE. Comparative inhibition of human cytochromes P450 1A1 and 1A2 by flavonoids. Drug Metab Dispos 1998;26:989-992.
54. Tsyrlov IB, Mikhailenko VM, Gelboin HV. Isozyme- and species-specific susceptibility of cDNA-expressed CYP1A P-450s to different flavonoids. Biochim Biophys Acta 1994;1205:325-335.
55. Doostdar H, Burke MD, Mayer RT. Bioflavonoids: Selective substrates and inhibitors for cytochrome P450 CYP1A and CYP1B1. Toxicology 2000;144:31-38.
56. Shimada T, Iwasaki M, Martin MV, Guengerich FP. Human liver microsomal cytochrome P-450 enzymes involved in the bioactivation of procarcinogens detected by umu gene response in Salmonella typhimurium TA 1535/pSK1002. Cancer Res 1989;49:3218-3228.
57. Rochat B, Morsman JM, Murray GI, Figg WD, Mcleod HL. Human CYP1B1 and anticancer agent metabolism: Mechanism for tumor-specific drug inactivation? J Pharmacol Exp Ther 2001;296:537-541.
58. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghom AD, Mehta RG, Moon RC, Pezzuto JM. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997;275:218-220.
59. Chun YJ, Kim MY, Guengerich FP. Resveratrol is a selective human cytochrome P450 1A1 inhibitor. Biochem Biophys Res Commun 1999;262:20-24.
60. Chang TK, Lee WB, Ko HH. Trans-resveratrol modulates the catalytic activity and mRNA expression of the procarcinogen-activating human cytochrome P450 1B1. Can J Physiol Pharmacol 2000;78:874-881.
61. Chun YJ, Ryu SY, Jeong TC, Kim MY. Mechanism-based inhibition of human cytochrome P450 1A1 by rhapontigenin. Drug Metab Dispos 2001;29:389-393.
62. Kim S, Ko H, Park JE, Jung S, Lee SK, Chun YJ. Design, synthesis, and discovery of novel trans-stilbene analogues as potent and selective human cytochrome P450 1B1 inhibitors. J Med Chem 2002;45:160-164.
63. Chun YJ, Kim S, Kim D, Lee SK, Guengerich FP. A new selective and potent inhibitor of human cytochrome P450 1B1 and its application to antimutagenesis. Cancer Res 2001;61:8164-8170.
64. Takahashi E, Fujita KI, Kamataki T, Arimoto-Kobayashi S, Okamoto K, Negishi T. Inhibition of human cytochrome P450 1B1, 1A1, and 1A2 by antigenotoxic compounds, purpurin and alizarin. Mutat Res 2002;508:147-156.
65. Shimada T, El-Bayoumy K, Upadhyaya P, Sutter TR, Guengerich FP, Yamazaki H. Inhibition of human cytochrome P450-catalyzed oxidations of xenobiotics and procarcinogens by synthetic organoselenium compounds. Cancer Res 1997;57:4757-4764.
66. Shimada T, Yamazaki H. Inhibition of human cytochrome P450-catalyzed oxidations of xenobiotics by synthetic organoselenium compounds. J Toxicol Sci 1997;22:354-354.
67. Langouët S, Furge LL, Kerriguy N, Nakamura K, Guillouzo A, Guengerich FP. Inhibition of human cytochrome P450 enzymes by 1,2-dithiole-3-thione, oltipraz and its derivatives, and sulforaphane. Chem Res Toxicol 2000;13:245-252.
68. Nakajima M, Yoshida R, Shimada N, Yamazaki H, Yokoi T. Inhibition and inactivation of human cytochrome P450 isoforms by phenethyl isothiocyanate. Drug Metab Dispos 2001;29:1110-1113.
69. Ueng YF, Jan WC, Lin LC, Chen TL, Guengerich FP, Chen CF. The alkaloid rutaecarpine is a selective inhibitor of cytochrome P450 1A in mouse and human liver microsomes. Drug Metab Dispos 2002;30:349-353.